228 related articles for article (PubMed ID: 20190365)
1. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
Takada J; Iba K; Yamashita T; Yoshizaki T
Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365
[TBL] [Abstract][Full Text] [Related]
2. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
Uusi-Rasi K; Semanick LM; Zanchetta JR; Bogado CE; Eriksen EF; Sato M; Beck TJ
Bone; 2005 Jun; 36(6):948-58. PubMed ID: 15878318
[TBL] [Abstract][Full Text] [Related]
3. [Effects of SERMs on bone health. Effects of raloxifene and bisphosphonate on bone quality in osteoporosis: collagen cross-links, mineralization, and bone strength].
Saito M
Clin Calcium; 2010 Mar; 20(3):345-54. PubMed ID: 20190364
[TBL] [Abstract][Full Text] [Related]
4. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
5. [Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2010 Mar; 20(3):315-21. PubMed ID: 20190360
[TBL] [Abstract][Full Text] [Related]
6. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
7. Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone.
Thiebaud D
J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S124-5. PubMed ID: 21213508
[No Abstract] [Full Text] [Related]
8. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study.
Borggrefe J; Graeff C; Nickelsen TN; Marin F; Glüer CC
J Bone Miner Res; 2010 Mar; 25(3):472-81. PubMed ID: 19778182
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.
Iwamoto J; Yeh JK; Schmidt A; Rowley E; Stanfield L; Takeda T; Sato M
Calcif Tissue Int; 2005 Aug; 77(2):119-26. PubMed ID: 16059775
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
Uyar Y; Baytur Y; Inceboz U; Demir BC; Gumuser G; Ozbilgin K
Maturitas; 2009 Jul; 63(3):261-7. PubMed ID: 19386450
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
[TBL] [Abstract][Full Text] [Related]
12. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
13. [Current topics in drug therapy aiming at bone resorption].
Yasui T; Tanaka S
Clin Calcium; 2006 Sep; 16(9):1475-79. PubMed ID: 16951471
[TBL] [Abstract][Full Text] [Related]
14. [SERM and quality of bone].
Sohen S
Clin Calcium; 2004 Oct; 14(10):96-9. PubMed ID: 15577138
[TBL] [Abstract][Full Text] [Related]
15. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
16. [Raloxifene hydrochloride].
Itabashi A
Nihon Rinsho; 2004 Feb; 62 Suppl 2():528-35. PubMed ID: 15035185
[No Abstract] [Full Text] [Related]
17. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P
Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
[TBL] [Abstract][Full Text] [Related]
18. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
[No Abstract] [Full Text] [Related]
19. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
20. Correlation between a bone resorption marker and structural geometry of the proximal femur in osteoporotic women treated with raloxifene.
Takada J; Iba K; Yoshizaki T; Yamashita T
J Orthop Surg (Hong Kong); 2012 Aug; 20(2):209-13. PubMed ID: 22933681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]